Cargando…

Prognostic Value of Short-Term Follow-up of Multiple Biomarkers After Discharge in Hospitalized Patients With Acute Heart Failure (POSTBIO-HF): Rationale and Study Design

Several surrogate biomarkers possess prognostic significance for heart failure (HF), and a decline in their respective values may predict clinical improvement. However, data on the prognostic value of these biomarkers during short-term follow-up after discharge in acute decompensated HF are scarce....

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Dong-Hyuk, Son, Jung-Woo, Lee, Chan Joo, Choi, Jimi, Kim, Mi-Na, Lee, Ju-Hee, Lee, Sunki, Yang, Dong Heon, Cho, Hyun-Jai, Choi, Jin-Oh, Kim, Eung Ju, Choi, Dong-Ju, Yoo, Byung-Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Heart Failure 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383348/
https://www.ncbi.nlm.nih.gov/pubmed/36263107
http://dx.doi.org/10.36628/ijhf.2022.0005
Descripción
Sumario:Several surrogate biomarkers possess prognostic significance for heart failure (HF), and a decline in their respective values may predict clinical improvement. However, data on the prognostic value of these biomarkers during short-term follow-up after discharge in acute decompensated HF are scarce. We aim to evaluate the prognostic value of short-term follow-up of surrogate biomarkers for predicting the prognosis of hospitalized patients with acute decompensated HF. This multi-center, prospective study will enroll consecutive hospitalized patients with acute decompensated HF. All patients will undergo sampling and comparison of biomarkers, including plasma N-terminal pro-brain natriuretic peptide, growth differentiation factor 15, troponin-T, high-sensitivity C-reactive protein, and urinary albumin/creatinine ratio obtained within 1 month and 6 months after discharge from the index admission. The primary endpoint is a composite of cardiovascular mortality or HF hospitalization during 1 year of follow-up. We will investigate the prognostic value of multiple biomarkers for the primary endpoint. This trial will provide robust evidence for novel multi-biomarker strategies for acute decompensated HF in real-world settings. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04437628